Universal cord blood screening for G6PD deficiency in Qatar

Jon F. Watchko
DOI: https://doi.org/10.1038/s41372-024-02146-4
2024-10-26
Journal of Perinatology
Abstract:Al-Bedaywi et al. are to be congratulated on reporting their extensive experience with universal cord blood screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency in Qatar [1]. Notably the results of their screening were available in short order and neonates found to be deficient underwent "close monitoring with transcutaneous bilirubin" measurements. In addition, a "dedicated G6PD deficiency screening team" educated the parents regarding the condition and ensured timely neonatal follow up in a dedicated bilirubin clinic [1]. The authors report 3 G6PD deficient babies in their cohort required an exchange transfusion. These 3 had total serum bilirubin (TSB) levels of 513 μmol/L (30 mg/dL) on day of life 4, 414 μmol/L (24.2 mg/dL) on day of life 2, and 616 μmol/L (36.0 mg/dL) on day of life 4. Can the authors share further details on the clinical courses of these three neonates including the results of their early bilirubin screening, whether the neonates were still in hospital or discharged when these elevated TSB levels were identified, whether these TSB levels reflected rebound hyperbilirubinemia following earlier phototherapy, and whether these TSB levels were a result of acute hemolytic events (and if so whether a hemolytic trigger was identified, e.g., sepsis). These details would be instructive for the readership as it is hoped that universal G6PD screening with close neonatal follow-up might prevent the development of hazardous hyperbilirubinemia in the G6PD deficient newborn.
pediatrics,obstetrics & gynecology
What problem does this paper attempt to address?